propagermanium
Small moleculeexperimental
Propagermanium (INN), also known by a variety of other names including bis(2-carboxyethylgermanium) sesquioxide and 2-carboxyethylgermasesquioxane, is an organometallic compound of germanium that is sold as an alternative medicine. It is a polymeric compound with the formula ((HOOCCH2CH2Ge)2O3)n. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01106469)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 2INHIBITOR
CCR2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPropagermanium ↗
- ChEMBLCHEMBL2109214 ↗
Also known as
- jnj-41443532
- jnj-41443532
- jnj-41443532
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03627715 | Phase 2 | Aug 31, 2018 | Dimerix Bioscience Pty Ltd, IQVIA |
| NCT03649152 | Phase 2 | Aug 31, 2018 | Dimerix Bioscience Pty Ltd, IQVIA |
| NCT01230749 | Phase 2 | Dec 1, 2010 | Johnson and Johnson |
| NCT01105780 | Phase 1 | May 1, 2010 | Johnson and Johnson |
| NCT01106469 | Phase 1 | Feb 1, 2010 | Johnson and Johnson |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 3 | 3 | 2 | 2010 |
| Dimerix Bioscience Pty Ltd | For profit | 2 | 2 | 1 | 2018 |
| IQVIA | For profit | 2 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1